The account points to tougher side effects at higher doses in new trial data and argues for gradual dose increases rather than pushing everyone to the max.
Recap by typeshit. Post by @osheahoganlabs on Instagram.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
Mayo's GI team highlights Atieh's feature, which looks past the scale to gains like better HbA1c and lipid profiles.
Ott covered emerging vaccine-style approaches using peptides, DNA and mRNA at a special symposium on melanoma.
Loading…